Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link Novo Nordisk's CagriSema Falls Short in Head to Head Trial vs Zepbound Bryce Platt, PharmD posted on the topic LinkedIn Cagrilintide 10mg NewBioRx